Can immunotherapy plus liver treatments open the door to transplants for more cancer patients?
Disease control
Recruiting now
This study is testing whether combining immunotherapy drugs (tremelimumab and durvalumab) with liver-directed procedures like TACE, TARE, or RFA can shrink liver cancer enough to make patients eligible for a liver transplant. The trial enrolls 41 adults with hepatocellular carcin…
Phase: PHASE2 • Sponsor: Ju Dong Yang • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC